search
Back to results

ACTH vs Betamethasone in Hospitalized Patients With Acute Gout

Primary Purpose

Gout Attack

Status
Unknown status
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
ACTH
Betamethasone
Sponsored by
University of Patras
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gout Attack focused on measuring gout, ACTH

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age>18 years
  2. able to provide written informed consent
  3. diagnosis of acute gout according to ACR/EULAR classification criteria -

Exclusion Criteria:

  1. pregnancy/lactation
  2. unable to provide written informed consent -

Sites / Locations

  • University Hospital of PatrasRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ACTH

Betamethasone

Arm Description

patients with acute gout treated with ACTH

patients with acute gout treated with betamethasone

Outcomes

Primary Outcome Measures

Pain VAS
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Pain VAS
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Pain VAS
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Pain VAS
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Pain VAS
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)

Secondary Outcome Measures

Physician global assessment
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Physician global assessment
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Physician global assessment
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Physician global assessment
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Patient global assessment
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Patient global assessment
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Patient global assessment
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Patient global assessment
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Tenderness
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Tenderness
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Tenderness
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Tenderness
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Swelling
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Swelling
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Swelling
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Swelling
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Redness
Redness rated using 0-3 scale (0=no redness, 3=severe redness)
Redness
Redness rated using 0-3 scale (0=no redness, 3=severe redrness)
Redness
Redness rated using 0-3 scale (0=no redness, 3=severe redness)
Redness
Redness rated using 0-3 scale (0=no redness, 3=severe redness)

Full Information

First Posted
February 14, 2020
Last Updated
March 12, 2020
Sponsor
University of Patras
search

1. Study Identification

Unique Protocol Identification Number
NCT04306653
Brief Title
ACTH vs Betamethasone in Hospitalized Patients With Acute Gout
Official Title
ACTH vs Betamethasone for the Treatment of Acute Gout in Hospitalized Patients: A Randomized, Open Label, Comparative Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
January 5, 2018 (Actual)
Primary Completion Date
April 2020 (Anticipated)
Study Completion Date
May 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Patras

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Hospitalized patients usually have significant comorbidities and receive multiple medications which leads to a high frequency of contraindications to standard treatment options for acute gout (NSAIDs, colchicine, steroids). Adrenocorticotropic hormone (ACTH) has long been used in acute gout, exhibiting significant clinical efficacy and an excellent safety profile. Aim: To assess 1) the clinical efficacy of ACTH in gout compared to betamethasone in hospitalized patients 2) the safety profile of ACTH vs betamethasone and 3) the effect of ACTH on immune responses and metabolic parameters. Methods: This is a randomized, open label comparative study directly comparing ACTH vs betamethasone for acute gout. The investigators plan to recruit 60 hospitalized patients who will be randomly assigned to either the ACTH or the betamethasone group on a 1:1 basis. Participants will be clinically assessed at baseline and at 24, 48, 72h and 5 days time points. (Intensity of pain, physician and patient global assessment, tenderness, swelling and redness). Serum and plasma samples will be collected at baseline and at the 24, 48, 72h time points from all study paticipants. The investigators will assess the effect of ACTH vs betamethasone on several metabolic parameters concentrating on glucose homeostasis. Results: The study is currently recruiting patients. Conclusions: If the efficacy and safety profile of ACTH is verified in this randomized controlled trial, the use of ACTH for the treatment of gout in the hospital setting will be strongly supported.
Detailed Description
BACKGROUND Treatment of gout can be either simple and straightforward in many cases, or extremely problematic in others. Current guidelines recommend the use of non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine as first-line treatment. However, patients with gout typically have multiple comorbidities that often preclude the use of these drugs. The management of gout can be even more troublesome in the hospital setting. Hospitalized patients usually have significant comorbidities and receive multiple medications, which lead to a high frequency of contraindications to the above agents. Steroids are considered an alternative therapeutic option especially for "difficult-to-treat" patients such as hospitalized patients. However they associate with immunosuppression and metabolic side effects; therefore, their use in the inpatient setting may be problematic as well. Adrenocorticotropic hormone (ACTH) has long been used in gout. The interest in ACTH was revived in the mid-1990s when several studies showed that ACTH is equally effective and, in most cases, acts faster than NSAIDs and steroids and exhibits an excellent safety profile. It was previously thought that the anti-inflammatory action of ACTH was steroid related: if this was the case, then one could argue that treatment with ACTH would have no advantage over the systemic administration of steroids. However, experimental evidence challenges this view; it has been shown that ACTH mainly acts in a steroid independent manner. The investigators have been using ACTH as a first-line treatment for hospitalized patients since 1995. The investigators have reported their experience with ACTH in gout in hospitalized patients - ACTH is highly effective and associates with minimal side effects. AIM To assess 1) the clinical efficacy of ACTH in gout compared to betamethasone in hospitalized patients; 2) the safety profile of ACTH vs betamethasone; and 3) the effect of ACTH on immune responses and metabolic parameters. HYPOTHESIS Based on retrospective data related to the use of ACTH in gout, the investigators hypothesize that ACTH has comparable clinical efficacy to betamethasone in the treatment of acute gout but exhibits a better safety profile and associates with less immunosuppression than betamethasone. STUDY DESIGN The investigators plan to recruit 60 hospitalized patients with acute gout. Participants will be randomly assigned to either the ACTH or the betamethasone group on a 1:1 basis. All participants will provide written informed consent. The study protocol has already been submitted and approved by the Ethics Committee of the University Hospital of Patras. The following data will be recorded for each participant: 1) age; 2) gender; 3) admission and discharge diagnosis; 4) history of major comorbidities that represent contraindications to established gout therapies; and 5) history history of hyperuricemia and gout. Comorbidities that will be recorded: a) hypertension defined as having a blood pressure (BP) of ≥140mmHg systolic and/or ≥90 mmHg diastolic and/or receiving any antihypertensive therapy; b) cardiovascular disease defined as the presence of coronary heart disease, cerebrovascular accident or peripheral vascular disease; c) chronic kidney disease defined as an estimated glomerular filtration rate, measured by the abbreviated Modification of Diet in Renal Disease formula of 60-90ml/min/1.73m2 (mild) or <60ml/ min/1.73m2 (moderate/severe); and d) diabetes mellitus (DM) defined as fasting serum glucose levels >126mg/ dl and/or the use of oral hypoglycemic medications or insulin. Particiopants will receive an IM injection of either 100 IU of ACTH (Synachten Depot) or 6 mg of betamethasone (Celestone Chronodose, which is the most commonly used intramuscular steroid formulation in our country and frequently used for the treatment of gout in the hospital setting. In case of partial or no response, participants will receive a second IM injection of the same drug at the 24h time point. Participants will be assessed at baseline and at 24, 48, 72h and 5-day time points. The clinical efficacy will be assessed as follows: Intensity of pain will be recorded using a Visual Analogue Scale (0-10 cm) at 24, 48, 72h and 5days time points. Pain VAS will be also recorded at the 6 and 12h time points (self reported by the patient on a special diary provided); Physician and patient global assessment (0-100 scale) at 24, 48, 72h and 5days time points; Tenderness, swelling and redness (0-3 scale) will be recorded at 24, 48, 72h and 5days time points. LABORATORY ANALYSIS The investigators aim to assess the effects of ACTH vs betamethasone on i) metabolic parameters and ii) immune responses. i) Metabolic parameters Serum and plasma samples will be collected at baseline and at the 24, 48, 72h time points from all study participants and will be stored at -70 oC. The investigators will assess the effect of ACTH vs betamethasone on several metabolic parameters concentrating on glucose homeostasis. The invstigators propose the measurement of the following molecules in serum samples collected at the time points specified above: 1) Fasting glucose, insulin and C-peptide so we can explore the effect of ACTH vs betamethasone on glucose homeostasis; 2) Total cholesterol, LDL, HDL and triglycerides so we can explore the effect of ACTH vs betamethasone on lipid homeostasis; 3) Cortisol levels in patients treated with ACTH. So far, the effect of a single IM ACTH injection of 100IU on cortisol levels is not known. The investigators hypothesize however, that cortisol levels will raise soon following the ACTH injection and decline shortly thereafter, thus causing minimum immunosuppression. In betamethasone treated patients the investigators propose the measurement of both Cortisol (using an assay with no cross reactivity with betamethasone) and ACTH levels. The investigators hypothesize that betamethasone will have a more pronounced effect on the HPA axis than ACTH and therefore may associate with a more intense and long-lasting immunosuppression; 4) Tetracosactide (Synachten) levels and betamethasone levels in ACTH and betamethasone treated patients respectively. Tetracosactide will be measured by ELISA methodology in plasma samples (Elisa Kit from Peninsula Laboratories, San Carlos, USA) that reacts with the part 1-24 of ACTH (and thus Tetracosactide). Plasma samples will be prepared by total elimination of endogenous ACTH by cation exchange chromatography. Similarly, betamethasone levels will be measured by ELISA methodology. With these experiments the investigators will explore how long tetracosactide and betamethasone circulate in peripheral blood following a single intramuscular injection. The investigators will match these data with the data derived from the experiments presented above (cortisol levels) to explore the effect of tetracosactide (Synachten) vs betamethasone on the HPA axis. ii) Effects on immune responses The investigators will study the effects of ACTH vs betamethasone on key cells mediating immune responses, such as a) T cells and b) neutrophils. The investigators propose the study of 10 patients (5 in the ACTH and 5 in the betamethasone group) matched for age and gender. These patients will not have active infection. A) Effects on T cells The investigators will collect 20 ml of heparinized peripheral blood at baseline and at the 24h time point. Peripheral blood mononuclear cells (PBMC) will be separated using a standard Ficoll centrifugation protocol and will be immediately stored in liquid nitrogen. The investigators estimate to collect 20X106 PBMC's from each sample. When all samples have been collected, the investigators will use flow cytometry to assess the expression of several activation markers on T cells. PBMC's will be stained with fluorochrome- conjugated monoclonal antibodies against CD3, CD40L, CD69 and CD25 and their respective isotypic controls. CD40L, CD69 and CD25 are typical T cell activation markers. Flow cytometry will be used to assess the percentage of CD3+ CD40L+, CD3+ CD69+ and CD3+ CD25+ double positive cells. The investigators also propose to assess these activation markers on T cells following activation. PBMC's will be cultured in RPMI supplemented with 15% FBS and antibiotics (pen/strep) for 48h. PHA at a concentration of 1μg/ml will be added to culture medium to activate T cells. Following 48h of culture, cells will be collected by centrifugation and analyzed as above using flow cytometry. In this experiment the investigators also plan to measure IL-2 levels in the culture supernatants since IL-2 is the main cytokine produced following T cell activation. With these experiments the investigators will explore the effects of ACTH vs betamethasone on T cells which are key cells mediating adaptive immune responses. The investigators hypothesize that ACTH has less effects on T cells compared to betamethasone. If this hypothesis is conformed by the experiments presented above, it will provide indirect evidence that ACTH causes less immunosuppression than steroids. SIGNIFICANCE OF THE STUDY This will be the first study to assess the efficacy of ACTH in gout in the hospital setting in a prospective manner. The investigators have previously reported that ACTH is highly effective in these patients and exhibits an excellent safety profile; however, these data were retrospectively collected. Therefore, if the efficacy and safety profile of ACTH is verified in this randomized controlled trial, the use of ACTH for the treatment of gout in the hospital setting will be strongly supported. However, the investigators believe that the laboratory part of the study will provide even more valuable data. If ACTH is proven to cause less metabolic abnormalities and associates with less immunosuppression compared to betamethasone, then ACTH may become the treatment of choice in this setting. Considering that hospitalized patients are the most difficult-to-treat patients, this may lead to wider use of ACTH in the treatment of gout in the community as well.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout Attack
Keywords
gout, ACTH

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ACTH
Arm Type
Experimental
Arm Description
patients with acute gout treated with ACTH
Arm Title
Betamethasone
Arm Type
Active Comparator
Arm Description
patients with acute gout treated with betamethasone
Intervention Type
Drug
Intervention Name(s)
ACTH
Intervention Description
patients with acute gout will receive 100 IU ACTH IM
Intervention Type
Drug
Intervention Name(s)
Betamethasone
Intervention Description
patients with acute gout will receive 6 mg of betamethasone
Primary Outcome Measure Information:
Title
Pain VAS
Description
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Time Frame
12 hours
Title
Pain VAS
Description
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Time Frame
24 hours
Title
Pain VAS
Description
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Time Frame
48 hours
Title
Pain VAS
Description
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Time Frame
72 hours
Title
Pain VAS
Description
Intensity of pain will be recorded using a Visual Analogue Scale (VAS) (0-10, 0=no pain 10=worst pain)
Time Frame
5 days
Secondary Outcome Measure Information:
Title
Physician global assessment
Description
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
24 hours
Title
Physician global assessment
Description
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
48 hours
Title
Physician global assessment
Description
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
72 hours
Title
Physician global assessment
Description
Physician global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
5 days
Title
Patient global assessment
Description
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
24 hours
Title
Patient global assessment
Description
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
48 hours
Title
Patient global assessment
Description
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
72 hours
Title
Patient global assessment
Description
Patient global assessment rated on a Visual Analogue Scale (VAS) (0-100, 0=very good, 100=very bad)
Time Frame
5 days
Title
Tenderness
Description
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Time Frame
24 hours
Title
Tenderness
Description
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Time Frame
48 hours
Title
Tenderness
Description
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Time Frame
72 hours
Title
Tenderness
Description
Tenderness rated using 0-3 scale (0=no tenderness, 3=severe tenderness)
Time Frame
5 days
Title
Swelling
Description
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Time Frame
24 hours
Title
Swelling
Description
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Time Frame
48 hours
Title
Swelling
Description
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Time Frame
72 hours
Title
Swelling
Description
Swelling rated using 0-3 scale (0=no swelling, 3=severe swelling)
Time Frame
5 days
Title
Redness
Description
Redness rated using 0-3 scale (0=no redness, 3=severe redness)
Time Frame
24 hours
Title
Redness
Description
Redness rated using 0-3 scale (0=no redness, 3=severe redrness)
Time Frame
48 hours
Title
Redness
Description
Redness rated using 0-3 scale (0=no redness, 3=severe redness)
Time Frame
72 hours
Title
Redness
Description
Redness rated using 0-3 scale (0=no redness, 3=severe redness)
Time Frame
5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age>18 years able to provide written informed consent diagnosis of acute gout according to ACR/EULAR classification criteria - Exclusion Criteria: pregnancy/lactation unable to provide written informed consent -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dimitrios Daoussis, MD, PhD
Phone
+302613603693
Email
jimdaoussis@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Panagiotis Kordas, MD
Phone
+306997265502
Email
panko_doc@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dimitrios Daoussis
Organizational Affiliation
University of Patras Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Patras
City
PAtras
State/Province
Achaia
ZIP/Postal Code
26500
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dimitrios Daoussis, MD, PhD
Phone
+302613603693
Email
jimdaoussis@hotmail.com
First Name & Middle Initial & Last Name & Degree
Panagiotis Kordas, MD
Phone
+306997265502
Email
panko_doc@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
7966077
Citation
Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994 Jul;21(7):1325-7.
Results Reference
background
PubMed Identifier
2454635
Citation
Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988 Jun;31(6):803-5. doi: 10.1002/art.1780310618.
Results Reference
background
PubMed Identifier
8035395
Citation
Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994 Apr;21(4):696-9.
Results Reference
background
PubMed Identifier
12384937
Citation
Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002 Oct;46(10):2765-75. doi: 10.1002/art.10526.
Results Reference
background
PubMed Identifier
17077300
Citation
Getting SJ, Lam CW, Chen AS, Grieco P, Perretti M. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J. 2006 Nov;20(13):2234-41. doi: 10.1096/fj.06-6339com.
Results Reference
background
PubMed Identifier
23195793
Citation
Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013 May;80(3):291-4. doi: 10.1016/j.jbspin.2012.09.009. Epub 2012 Nov 26.
Results Reference
background
PubMed Identifier
22195044
Citation
Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, Drosos GI, Boumpas DT, Ritis K. Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLoS One. 2011;6(12):e29318. doi: 10.1371/journal.pone.0029318. Epub 2011 Dec 16.
Results Reference
background
PubMed Identifier
26347989
Citation
Gavillet M, Martinod K, Renella R, Harris C, Shapiro NI, Wagner DD, Williams DA. Flow cytometric assay for direct quantification of neutrophil extracellular traps in blood samples. Am J Hematol. 2015 Dec;90(12):1155-8. doi: 10.1002/ajh.24185. Epub 2015 Oct 6.
Results Reference
background
PubMed Identifier
23024028
Citation
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772. No abstract available.
Results Reference
result
PubMed Identifier
21295195
Citation
Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011 Feb;124(2):155-63. doi: 10.1016/j.amjmed.2010.09.012.
Results Reference
result
PubMed Identifier
24762710
Citation
Daoussis D, Antonopoulos I, Andonopoulos AP. ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action. Semin Arthritis Rheum. 2014 Apr;43(5):648-53. doi: 10.1016/j.semarthrit.2013.09.006. Epub 2013 Oct 5.
Results Reference
result
PubMed Identifier
35445840
Citation
Daoussis D, Kordas P, Varelas G, Michalaki M, Onoufriou A, Mamali I, Iliopoulos G, Melissaropoulos K, Ntelis K, Velissaris D, Tzimas G, Georgiou P, Vamvakopoulou S, Paliogianni F, Andonopoulos AP, Georgopoulos N. ACTH vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study. Rheumatol Int. 2022 Jun;42(6):949-958. doi: 10.1007/s00296-022-05128-x. Epub 2022 Apr 21.
Results Reference
derived

Learn more about this trial

ACTH vs Betamethasone in Hospitalized Patients With Acute Gout

We'll reach out to this number within 24 hrs